sugammadex (bridion) Report issue

Small molecule Approved FDA First in Class Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Sugammadex (ORG 25969) is a cyclodextrin derivative was synthesized as synthetic receptor (or host molecule) for neuromuscular blockers (rocuronium and vecuronium). It forms a complex with the neuromuscular blocking agents rocuronium and vecuronium, and it reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade induced by rocuronium and vecuronium. The clinical use of sugammadex promises to eliminate many of the shortcomings in current anesthetic practice with regard to antagonism of rocuronium and other aminosteroid muscle relaxants. Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.   NCATS

Chemistry

  • SMILES: O=C(O)CCSC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O[C@H]9[C@H](O)C(O)[C@@H](O[C@H]1[C@H](O)[C@H]2O)O[C@@H]9CSCCC(=O)O)O[C@@H]8CSCCC(=O)O)O[C@@H]7CSCCC(=O)O)O[C@@H]6CSCCC(=O)O)O[C@@H]5CSCCC(=O)O)O[C@@H]4CSCCC(=O)O)O[C@@H]3CSCCC(=O)O
  • InChIKey: WHRODDIHRRDWEW-ZWYCLXBASA-N
  • Mol. Mass: 2002.18
  • ALogP: Missing data
  • ChEMBL Molecules:
    sugammadex  
    sugammadex sodium  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$72.7410 - $176.3720
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

6-perdeoxy-6-per(2-carboxyethyl)thio-gamma-cyclodextrin sodium salt | bridion | org 25969 | org-25969 | sugammadex | sugammadex sodium | suggamadex

Organizations (142)

Research & Development (133)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (101)

Approved Indications (1)


 

Neuromuscular Blockade

Experimental Indications - Clinical Trial Phases 1-4 (101)


 

Acute-On-Chronic Liver Failure (Phase 4)

Anaphylaxis (Phase 1)

Anesthesia (Phase 4)

Anesthesia and Analgesia (Phase 4)

Anesthesia, General (Phase 4)

Anesthesia Recovery Period (Phase 4)

Anesthesia, Spinal (Phase 4)

Anesthesiology (Phase 4)

Aorta (Phase 4)

Appendicitis (Phase 4)

Arthroplasty, Replacement, Hip (Phase 3)

Arthroplasty, Replacement, Knee (Phase 3)

Bariatric Surgery (Phase 3)

beta-Thalassemia (Phase 2/Phase 3)

Blood Coagulation (Phase 3)

Blood Pressure (Phase 4)

Brain Neoplasms (Phase 4)

Bronchoscopy (Phase 4)

Burns (Phase 3)

Cervix Uteri (Phase 4)

Cesarean Section (Phase 4)

Cholecystectomy, Laparoscopic (Phase 4)

Cholecystitis (Phase 4)

Coronary Artery Disease (Phase 4)

COVID-19 (Phase 4)

Delayed Emergence from Anesthesia (Phase 4)

Diaphragm (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Elective Surgical Procedures (Phase 3)

Electromyography (Phase 4)

Emergence Delirium (Phase 4)

Endometriosis (Phase 4)

Esophageal and Gastric Varices (Phase 4)

Extracorporeal Membrane Oxygenation (Phase 4)

Fibrinolytic Agents (Phase 3)

Gallbladder Diseases (Phase 4)

General Surgery (Phase 4)

Gynecology (Phase 4)

Heart Failure (Phase 4)

Heart Valve Diseases (Phase 4)

Hepatoblastoma (Phase 2/Phase 3)

Hernia, Ventral (Phase 4)

High-Frequency Jet Ventilation (Phase 1)

Hip Fractures (Phase 4)

Hypersensitivity (Phase 1)

Ileus (Phase 4)

Inflammation (Phase 2)

Intestinal Diseases (Phase 4)

Kidney Diseases (Phase 1)

Kidney Failure, Chronic (Phase 4)

Kidney Transplantation (Phase 4)

Laparoscopy (Phase 4)

Laryngoscopy (Phase 4)

Leiomyoma (Phase 4)

Leukemia, Lymphoid (Phase 4)

Liver Diseases (Phase 4)

Lung Diseases (Phase 4)

Lymphoma (Phase 2/Phase 3)

Mobility Limitation (Phase 4)

Muscle Fatigue (Phase 3)

Muscle Relaxants, Central (Phase 4)

Muscle Relaxation (Phase 4)

Muscle Weakness (Phase 3)

Nausea (Phase 4)

Neoplasm Metastasis (Phase 4)

Neoplasms (Phase 4)

Neostigmine (Phase 4)

Neuromuscular Blockade (Phase 4)

Neuromuscular Blocking Agents (Early Phase 1)

Obesity (Phase 4)

Obesity, Morbid (Phase 2/Phase 3)

Organophosphate Poisoning (Phase 2/Phase 3)

Osteoarthritis, Hip (Phase 2)

Pain, Postoperative (Phase 4)

Pharmacokinetics (Phase 4)

Physiological Effects of Drugs (Early Phase 1)

Pneumoperitoneum (Phase 4)

Postoperative Complications (Phase 4)

Postoperative Nausea and Vomiting (Phase 4)

Pre-Eclampsia (Phase 4)

Pregnancy (Phase 4)

Prostatic Neoplasms (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Rapid Sequence Induction and Intubation (Phase 4)

Renal Insufficiency (Phase 1)

Renal Insufficiency, Chronic (Phase 4)

Respiratory-Gated Imaging Techniques (Phase 4)

Respiratory Insufficiency (Phase 4)

Respiratory Muscles (Phase 4)

Rocuronium (Phase 4)

Sleep Apnea, Obstructive (Phase 4)

Smoking (Phase 4)

Spinal Curvatures (Phase 4)

Spinal Diseases (Phase 4)

Strabismus (Phase 4)

Sugammadex (Phase 4)

Ultrasonography (Phase 4)

Urinary Bladder Neoplasms (Phase 4)

Uterine Prolapse (Phase 4)

Ventilators, Mechanical (Phase 4)

Vocal Cord Dysfunction (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 215
  • # of Trial Organizations: 133

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue